Cellantra Announces Discovery of Potent Novel MAGE-C2-Targeting TCR Candidate for Cancer Immunotherapy
CellantraTechTech Announces Discovery of Potent Novel MAGE-C2-Targeting TCR Candidate for Cancer Immunotherapy
Uncategorized
CellantraTech AND CAPSTAN SIGN COOPERATION MEMORANDUM TO ADVANCE IN VIVO CAR-T THERAPIES FOR SOLID TUMORS
CellantraTech AND CAPSTAN SIGN COOPERATION MEMORANDUM TO ADVANCE IN VIVO CAR-T THERAPIES FOR SOLID TUMORS
Cellantra Files Patent Application Covering A20T013, an αvβ6-Binding Monobody Designed as a Modular Address Ligand for Gene Delivery
CellantraTechTech Files Patent Application Covering A20T013, an αvβ6-Binding Monobody Designed as a Modular Address Ligand for Gene Delivery
Cellantra Files Patent Application Covering G059, a Proprietary Surface-Targeting Ligand for Precision Gene Delivery
CellantraTechTech Files Patent Application Covering G059, a Proprietary Surface-Targeting Ligand for Precision Gene Delivery
Cellantra Announces Discovery of Novel MAGE-C1-Targeting TCR Candidate for Cancer Immunotherapy
CellantraTechTech Announces Discovery of Novel MAGE-C1-Targeting TCR Candidate for Cancer Immunotherapy
